Dihydroergotamine Mesylate Spray
Product Images NDC 73352-096

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dihydroergotamine Mesylate (NDC 73352-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Trifluent Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Inner Label A)

Label for Dihydroergotamine Mesylate nasal spray, 4 mg/mL, including 1 vial and 1 sprayer. The label indicates it is Rx only, for nasal use only and not for injection, marketed by Trifluent Pharma. It advises storage below 25°C (77°F) without refrigeration or freezing and includes a note on migraine therapy administration instructions.*

FDA Label Image

Image Description (Outer Label A)

Dihydroergotamine Mesylate nasal spray 4 mg/mL (1 mL/vial) packaging label from Trifluent Pharma, LLC. The label indicates this kit contains 8 vials and 8 nasal sprayers, along with administration and package inserts. It is for nasal use only and not for injection, with storage instructions below 25°C (77°F).*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 1a)

A line graph showing the estimated probability of a patient responding during the four hours following a single 2 mg dose of dihydroergotamine mesylate nasal spray. The x-axis represents time from the first dose in hours (0 to 4), and the y-axis shows the estimated probability of response to study medication in percentage (0 to 100%). Two lines compare dihydroergotamine mesylate nasal spray versus placebo over time, with the nasal spray showing higher response probabilities.*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 2a)

A line graph illustrating the estimated probability of a patient responding to dihydroergotamine mesylate nasal spray compared to placebo during the four hours following dosing. The x-axis represents time from first dose in hours (0 to 4), and the y-axis shows the estimated probability of response to study medication in percentage (0% to 100%). Two lines are plotted: one for dihydroergotamine mesylate nasal spray and one for placebo, with the nasal spray line showing a higher probability of response over time. The graph is based on studies 3 and 4, with sample sizes of 97 for nasal spray and 100 for placebo.*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 3a)

A line graph showing the estimated probability of patients using additional treatments for migraine over 24 hours after using dihydroergotamine mesylate nasal spray 2 mg or placebo. The x-axis represents hours after the first spray (0 to 24), and the y-axis represents the estimated probability of analgesic use (0% to 100%). Two lines compare dihydroergotamine mesylate nasal spray with placebo.*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Structure A)

Chemical structure of dihydroergotamine mesylate is shown with its molecular formula (C33H37N5O5•CH4O3S) and molecular weight (679.80). The diagram includes rings, chains, and functional groups depicting the molecular configuration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.